Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) has announced this morning that the company has signed an agreement with one of the leading e-commerce development platforms in the world, Shopify Inc. (TSX: SHOP).
The two corporations will work synergistically to develop a new platform for Aurora Cannabis’s global networks of medicinal and recreational cannabis customers.
Shopify, which was founded in 2006, is headquartered out of Ontario, Canada. The company provides online commerce systems and currently works with 600,000 different merchants across the globe. Shopify works with large corporations such as Amazon, Ebay, Enterprise, Facebook, and Pinterest to help them streamline online payment processing to assist with consumers selling goods and services.
Aurora plans to work closely with Shopify’s software engineer team to newly develop a e-commerece website designed specifically for Aurora Cannabis’s patients and customers. Aurora expects the new system to rapidly streamline communication with customers and to create a platform easily scalable to satisfy the company expected growth. Shopify is available on all IOS and Android devices.
“Selecting Shopify allows Aurora to bring a world-class ecommerce solution to our patients and future adult consumer use customers,” said Darryl Vleeming, CIO of Aurora Cannabis Inc. “Shopify’s unique, industry leading platform provides a safe, secure and flexible ecommerce site that we can build on as we execute our global growth initiatives and enter new markets.”
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…